{"id":495862,"date":"2020-07-14T13:42:01","date_gmt":"2020-07-14T13:42:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=495862"},"modified":"2020-07-14T13:42:01","modified_gmt":"2020-07-14T13:42:01","slug":"nonsmall-cell-lung-cancer-market-is-expected-to-increase-with-a-cagr-of-107-for-the-study-period-of-20172030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/nonsmall-cell-lung-cancer-market-is-expected-to-increase-with-a-cagr-of-107-for-the-study-period-of-20172030_495862.html","title":{"rendered":"\ufeffNon-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1594712115.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"\ufeffNon-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030\" src=\"https:\/\/www.abnewswire.com\/uploads\/1594712115.jpeg\" alt=\"\ufeffNon-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u2018Non-Small Cell Lung Cancer (NSCLC) &#8211; Market Insights, Epidemiology and Market Forecast &#8211; 2030\u2019 report delivers an in-depth understanding of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Non-Small Cell Lung Cancer market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.<\/div>\n<p style=\"text-align: justify;\">DelveInsight has introduced a new report on &#8220;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-market\"  target=\"_blank\">Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030<\/a><\/strong>&#8221; to its portfolio.<\/p>\n<p style=\"text-align: justify;\">The growth of NSCLC Market is expected to increase due to increasing incident cases of NSCLC, continuous uptake of approved therapies mainly immune checkpoint inhibitors, increasing use of biomarker testing, probable entry of potential premium price emerging therapies and increasing awareness of mutations, among others.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Highlights from the report are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017. These cases are expected to grow with a significant CAGR in the study period 2017&ndash;2030.<\/li>\n<li>There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.<\/li>\n<li>The market size of NSCLC in the 7MM is expected to increase during study period. According to the estimates, the highest contribution in the market size of NSCLC is from&nbsp;<span class=\"xn-location\">the United States<\/span>&nbsp;followed by&nbsp;<span class=\"xn-location\">Japan<\/span>,&nbsp;<span class=\"xn-location\">Germany<\/span>, and the UK.<\/li>\n<li>One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/non-small-cell-lung-cancer-market\"  target=\"_blank\">Request for free sample pages to get a detailed view on&nbsp;Non-Small Cell Lung Cancer Market Forecast&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers. The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as&nbsp;<em>Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation\/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies<\/em>&nbsp;scenario of NSCLC in the 7MM.<\/p>\n<p style=\"text-align: justify;\"><strong>The total NSCLC incident cases in the 7MM were observed to be 484,726 cases in 2017.<\/strong><\/p>\n<p style=\"text-align: justify;\">NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena\/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.<\/p>\n<p style=\"text-align: justify;\"><strong>Drugs covered in the report are:-<\/strong><\/p>\n<p style=\"text-align: justify;\">There are several key players robustly involved in developing potential products such as<\/p>\n<ul style=\"text-align: justify;\">\n<li>Nazartinib (EGF816)<\/li>\n<li>Capmatinib (INC280)<\/li>\n<li>Tepmetko (tepotinib)<\/li>\n<li>Merestinib<\/li>\n<li>JNJ-61186372 (JNJ-6372)<\/li>\n<li>Vemurafenib Plus Cobimetinib<\/li>\n<li>X-396 (Ensartinib)<\/li>\n<li>Tedopi (OSE2101)<\/li>\n<li>Selpercatinib (LY3527723\/ LOXO-292)<\/li>\n<li><span class=\"xn-money\">SAR408701<\/span><\/li>\n<li>Braftovi (encorafinib) + Mektovi (binimetinib)<\/li>\n<li>PADCEV (enfortumab vedotin\/ASG-22ME)<\/li>\n<li>Pralsetinib (BLU-667)<\/li>\n<li>TAK-788: Canakinumab (ACZ885)<\/li>\n<li>Avelumab (Bavencio)<\/li>\n<li>Veliparib (ABT-888): Sitravatinib (MGCD516)<\/li>\n<li>Tesevatinib<\/li>\n<li>Romiplostim: Cabozantinib<\/li>\n<li>Sym015<\/li>\n<li>AMG 510<\/li>\n<li>INCMGA00012 (MGA012)<\/li>\n<li>Libtayo (Cemiplimab)<\/li>\n<li>Bavituximab<\/li>\n<li>M7824 (Bintrafusp alfa)<\/li>\n<li>And many others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Key Players covered in the report are:-<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Novartis Pharmaceuticals<\/li>\n<li>Merck KGaA<\/li>\n<li>Eli Lilly and Company<\/li>\n<li>Janssen Research &amp; Development<\/li>\n<li>Hoffmann-La Roche<\/li>\n<li>Xcovery<\/li>\n<li>BeyondSpring Pharmaceuticals<\/li>\n<li>OSE Immunotherapeutics<\/li>\n<li>Sanofi<\/li>\n<li>Pfizer<\/li>\n<li>Astellas Pharma<\/li>\n<li>Seattle Genetics<\/li>\n<li>Blueprint Medicines Corporation<\/li>\n<li>Takeda<\/li>\n<li>AbbVie<\/li>\n<li>Kadmon Corporation<\/li>\n<li>Amgen<\/li>\n<li>Symphogen<\/li>\n<li>Regeneron Pharmaceuticals<\/li>\n<li>Peregrine Pharmaceuticals<\/li>\n<li>Avid Bioservices<\/li>\n<li>GlaxoSmithKline<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And many others<\/p>\n<p style=\"text-align: justify;\"><strong>Table of contents:<\/strong><\/p>\n<div class=\"course-details\" style=\"text-align: justify;\">\n<div class=\"tab-content\">\n<div id=\"curriculum\" class=\"tab-pane ql-editor with-listing only-with-listing fade active in\">\n<p><span>1.&nbsp;&nbsp;&nbsp;Key Insights<\/span><\/p>\n<p><span>2.&nbsp;&nbsp;&nbsp;Executive Summary of NSCLC<\/span><\/p>\n<p><span>3.&nbsp;&nbsp;&nbsp;SWOT Analysis of NSCLC<\/span><\/p>\n<p><span>4.&nbsp;&nbsp;&nbsp;NSCLC: Market Overview at a Glance<\/span><\/p>\n<p><span>4.1.&nbsp;&nbsp;Total Market Share (%) Distribution of NSCLC in 2017: By Country<\/span><\/p>\n<p><span>4.2.&nbsp;&nbsp;Total Market Share (%) Distribution of NSCLC in 2030: By Country<\/span><\/p>\n<p><span>4.3.&nbsp;&nbsp;Total Market Share (%) Distribution of NSCLC in 2017: By Mutations\/ biomarkers<\/span><\/p>\n<p><span>4.4.&nbsp;&nbsp;Total Market Share (%) Distribution of NSCLC in 2030: By Mutations\/ biomarkers<\/span><\/p>\n<p><span>4.5.&nbsp;&nbsp;NSCLC Revenue Summary by Mutations\/ biomarkers<\/span><\/p>\n<p><span>5.&nbsp;&nbsp;&nbsp;Non-small Cell Lung Cancer (NSCLC): Disease Background and Overview<\/span><\/p>\n<p><span>5.1.&nbsp;&nbsp;Introduction<\/span><\/p>\n<p><span>5.1.1. Cellular Classification of NSCLC<\/span><\/p>\n<p><span>5.1.2.&nbsp;Signs and Symptoms of NSCLC<\/span><\/p>\n<p><span>5.1.3. Risk Factors of Lung Cancer<\/span><\/p>\n<p><span>5.1.4.&nbsp;Causes of NSCLC<\/span><\/p>\n<p><span>5.1.5.&nbsp;Disease Biology: NSCLC<\/span><\/p>\n<p><span>6.&nbsp;&nbsp;&nbsp;Diagnosis of NSCLC<\/span><\/p>\n<p><span>6.1.&nbsp;&nbsp;Diagnostic Algorithm for NSCLC<\/span><\/p>\n<p><span>6.2.&nbsp;&nbsp;Stages of NSCLC<\/span><\/p>\n<p><span>6.3.&nbsp;&nbsp;Staging System<\/span><\/p>\n<p><span>7.&nbsp;&nbsp;&nbsp;Epidemiology and Patient Population<\/span><\/p>\n<p><span>7.1.&nbsp;&nbsp;Epidemiology Key Findings<\/span><\/p>\n<p><span>7.2.&nbsp;&nbsp;Assumptions and Rationale: 7MM<\/span><\/p>\n<p><span>7.3.&nbsp;&nbsp;Epidemiology Scenario: 7MM<\/span><\/p>\n<p><span>7.3.1. Total Incident cases of NSCLC patients in the 7MM<\/span><\/p>\n<p><span>7.3.2.&nbsp;Total Incident cases of NSCLC patients by Histology in the 7MM<\/span><\/p>\n<p><span>7.3.3.&nbsp;Total Diagnosed cases of NSCLC patients by Stages in the 7MM<\/span><\/p>\n<p><span>7.4.&nbsp;The United States Epidemiology<\/span><\/p>\n<p><span>7.4.1.&nbsp;Total Incident cases of NSCLC patients in the United States<\/span><\/p>\n<p><span>7.4.2.&nbsp;Total Incident cases of NSCLC patients by Histology in the United States<\/span><\/p>\n<p><span>7.4.3. Total Diagnosed cases of NSCLC patients by Stages in the United States<\/span><\/p>\n<p><span>7.4.4. Total NSCLC cases of patients by Genetic mutation\/Biomarkers in the United States<\/span><\/p>\n<p><span>8.&nbsp;&nbsp;&nbsp;EU-5 Epidemiology<\/span><\/p>\n<p><span>8.1.&nbsp;&nbsp;Germany<\/span><\/p>\n<p><span>8.1.1. Total Incident cases of NSCLC patients in Germany<\/span><\/p>\n<p><span>8.1.2.&nbsp;Total Incident cases of NSCLC patients by Histology in Germany<\/span><\/p>\n<p><span>8.1.3.&nbsp;Total Diagnosed cases of NSCLC patients by Stages in Germany<\/span><\/p>\n<p><span>8.1.4.&nbsp;Total NSCLC cases of patients by Genetic mutation\/Biomarkers in Germany<\/span><\/p>\n<p><span>8.2.&nbsp;&nbsp;France<\/span><\/p>\n<p><span>8.2.1. Total Incident cases of NSCLC patients in France<\/span><\/p>\n<p><span>8.2.2.&nbsp;Total Incident cases of NSCLC patients by Histology in France<\/span><\/p>\n<p><span>8.2.3.&nbsp;Total Diagnosed cases of NSCLC patients by Stages in France<\/span><\/p>\n<p><span>8.2.4.&nbsp;Total NSCLC cases of patients by Genetic mutation\/Biomarkers in France<\/span><\/p>\n<p><span>8.3.&nbsp;&nbsp;Italy<\/span><\/p>\n<p><span>8.3.1.&nbsp;Total Incident cases of NSCLC patients in Italy<\/span><\/p>\n<p><span>8.3.2.&nbsp;Total Incident cases of NSCLC patients by Histology in Italy<\/span><\/p>\n<p><span>8.3.3.&nbsp;Total Diagnosed cases of NSCLC patients by Stages in Italy<\/span><\/p>\n<p><span>8.3.4.&nbsp;Total NSCLC cases of patients by Genetic mutation\/Biomarkers in Italy<\/span><\/p>\n<p><span>8.4.&nbsp;&nbsp;Spain<\/span><\/p>\n<p><span>8.4.1.&nbsp;Total Incident cases of NSCLC patients in Spain<\/span><\/p>\n<p><span>8.4.2.&nbsp;Total Incident cases of NSCLC patients by Histology in Spain<\/span><\/p>\n<p><span>8.4.3.&nbsp;Total Diagnosed cases of NSCLC patients by Stages in Spain<\/span><\/p>\n<p><span>8.4.4.&nbsp;Total NSCLC cases of patients by Genetic mutation\/Biomarkers in Spain<\/span><\/p>\n<p><span>8.5.&nbsp;&nbsp;The United Kingdom<\/span><\/p>\n<p><span>8.5.1.&nbsp;Total Incident cases of NSCLC patients in the United Kingdom<\/span><\/p>\n<p><span>8.5.2.&nbsp;Total Incident cases of NSCLC patients by Histology in the United Kingdom<\/span><\/p>\n<p><span>8.5.3.&nbsp;Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom<\/span><\/p>\n<p><span>8.5.4.&nbsp;Total NSCLC cases of patients by Genetic mutation\/Biomarkers in the United Kingdom<\/span><\/p>\n<p><span>9.&nbsp;&nbsp;&nbsp;Japan Epidemiology<\/span><\/p>\n<p><span>9.1.&nbsp;&nbsp;Japan<\/span><\/p>\n<p><span>9.1.1.&nbsp;Total Incident cases of NSCLC patients in Japan<\/span><\/p>\n<p><span>9.1.2.&nbsp;Total Incident cases of NSCLC patients by Histology in Japan<\/span><\/p>\n<p><span>9.1.3.&nbsp;Total Diagnosed cases of NSCLC patients by Stages in Japan<\/span><\/p>\n<p><span>9.1.4.&nbsp;Total NSCLC cases of patients by Genetic mutation\/Biomarkers in Japan<\/span><\/p>\n<p><span>10. Current Treatment Practices: NSCLC<\/span><\/p>\n<p><span>10.1.&nbsp;&nbsp;Advanced\/Metastatic NSCLC Treatment Algorithm<\/span><\/p>\n<p><span>10.2.&nbsp;&nbsp;Chemotherapy<\/span><\/p>\n<p><span>10.3.&nbsp;&nbsp;Targeted Therapy<\/span><\/p>\n<p><span>10.4.&nbsp;&nbsp;Immunotherapy<\/span><\/p>\n<p><span>10.5.&nbsp;&nbsp;Surgery<\/span><\/p>\n<p><span>10.6.&nbsp;&nbsp;Radiation Therapy<\/span><\/p>\n<p><span>10.7.&nbsp;&nbsp;Stage-wise Treatment Options of NSCLC<\/span><\/p>\n<p><span>11. Guideline of NSCLC<\/span><\/p>\n<p><span>11.1.&nbsp;&nbsp;The National Comprehensive Cancer Network (NCCN) Clinical Guidelines: 2020<\/span><\/p>\n<p><span>11.2.&nbsp;&nbsp;The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up<\/span><\/p>\n<p><span>11.3.&nbsp;&nbsp;The Spanish Society of Medical Oncology (SEOM) Clinical Guidelines: 2018<\/span><\/p>\n<p><span>11.4.&nbsp;&nbsp;The Japanese Lung Cancer Society Guideline for NSCLC, Stage IV: 2018<\/span><\/p>\n<p><span>12. Unmet Needs of NSCLC<\/span><\/p>\n<p><span>13. Key Endpoints in NSCLC Clinical Trials<\/span><\/p>\n<p><span>14. Marketed Therapies<\/span><\/p>\n<p><span>14.1.&nbsp;Key Cross<\/span><\/p>\n<p><span>14.2.&nbsp;Rozlytrek (Entrectinib): Hoffmann-La Roche (Genentech)<\/span><\/p>\n<p><span>14.2.1.&nbsp;Product Description<\/span><\/p>\n<p><span>14.2.2.&nbsp;Regulatory Milestones<\/span><\/p>\n<p><span>14.2.3.&nbsp;Other Developmental Activities<\/span><\/p>\n<p><span>14.2.4.&nbsp;Pivotal Clinical Trials<\/span><\/p>\n<p><span>14.2.5.&nbsp;Ongoing Current Pipeline Activity<\/span><\/p>\n<p><span>14.3.&nbsp;Imfinzi (Durvalumab): AstraZeneca<\/span><\/p>\n<p><span>14.3.1.&nbsp;Product Description<\/span><\/p>\n<p><span>14.3.2.&nbsp;Regulatory Milestones<\/span><\/p>\n<p><span>14.3.3.&nbsp;Other Developmental Activities<\/span><\/p>\n<p><span>14.3.4.&nbsp;Pivotal Clinical Trials<\/span><\/p>\n<p><span>14.3.5.&nbsp;Ongoing Current Pipeline Activity<\/span><\/p>\n<p><span>14.3.6.&nbsp;Safety and Efficacy of Ongoing Clinical Trials<\/span><\/p>\n<p><span>14.4.&nbsp;Opdivo (Nivolumab): Bristol-Myers Squibb<\/span><\/p>\n<p><span>14.4.1.&nbsp;Product Description<\/span><\/p>\n<p><span>14.4.2.&nbsp;Regulatory Milestones<\/span><\/p>\n<p><span>14.4.3.&nbsp;Other Developmental Activities<\/span><\/p>\n<p><span>14.4.4.&nbsp;Pivotal Clinical Trials<\/span><\/p>\n<p><span>14.4.5.&nbsp;Ongoing Current Pipeline Activity<\/span><\/p>\n<p><span>14.5.&nbsp;Tecentriq (Atezolizumab): Genentech\/Hoffmann-La Roche<\/span><\/p>\n<p><span>14.5.1.&nbsp;Product Description<\/span><\/p>\n<p><span>14.5.2.&nbsp;Regulatory Milestones<\/span><\/p>\n<p><span>14.5.3.&nbsp;Other Developmental Activities<\/span><\/p>\n<p><span>14.5.4.&nbsp;Pivotal Clinical Trials<\/span><\/p>\n<p><span>14.5.5.&nbsp;Ongoing Current Pipeline Activity<\/span><\/p>\n<p><span>14.6.&nbsp;Keytruda (Pembrolizumab): Merck<\/span><\/p>\n<p><span>14.6.1.&nbsp;Product Description<\/span><\/p>\n<p><span>14.6.2.&nbsp;Regulatory Milestones<\/span><\/p>\n<p><span>14.6.3.&nbsp;Other Developmental Activities<\/span><\/p>\n<p><span>14.6.4.&nbsp;Pivotal Clinical Trials<\/span><\/p>\n<p><span>14.6.5.&nbsp;Ongoing Current Pipeline Activity<\/span><\/p>\n<p><span>14.7.&nbsp;Tafinlar(Dabrafenib)in Combination with Mekinist(Trametinib): Novartis<\/span><\/p>\n<p><span>14.7.1.&nbsp;Product Description<\/span><\/p>\n<p><span>14.7.2.&nbsp;Regulatory Milestones<\/span><\/p>\n<p><span>14.7.3.&nbsp;Other Developmental Activities<\/span><\/p>\n<p><span>14.7.4.&nbsp;Pivotal Clinical Trials<\/span><\/p>\n<p><span>14.8.&nbsp;Tagrisso(Osimertinib): AstraZeneca<\/span><\/p>\n<p><span>14.8.1.&nbsp;Product Description<\/span><\/p>\n<p><span>14.8.2.&nbsp;Regulatory Milestones<\/span><\/p>\n<p><span>14.8.3.&nbsp;Other Developmental Activities<\/span><\/p>\n<p><span>14.8.4.&nbsp;Pivotal Clinical Trials<\/span><\/p>\n<p><span>14.8.5.&nbsp;Ongoing Current Pipeline Activity<\/span><\/p>\n<p><span>14.9.&nbsp;Lorbrena\/Lorviqua (Lorlatinib): Pfizer<\/span><\/p>\n<p><span>14.9.1.&nbsp;Product Description<\/span><\/p>\n<p><span>14.9.2.&nbsp;Regulatory Milestones<\/span><\/p>\n<p><span>14.9.3.&nbsp;Other Developmental Activities<\/span><\/p>\n<p><span>14.9.4.&nbsp;Pivotal Clinical Trials<\/span><\/p>\n<p><span>14.9.5.&nbsp;Ongoing Current Pipeline Activity<\/span><\/p>\n<p><span>14.10.&nbsp;Vizimpro(Dacomitinib): Pfizer<\/span><\/p>\n<p><span>14.10.1.&nbsp;Product Description<\/span><\/p>\n<p><span>14.10.2.&nbsp;Regulatory Milestones<\/span><\/p>\n<p><span>14.10.3.&nbsp;Other Developmental Activities<\/span><\/p>\n<p><span>14.10.4.&nbsp;Pivotal Clinical Trials<\/span><\/p>\n<p><span>14.10.5.&nbsp;Ongoing Current Pipeline Activity<\/span><\/p>\n<p><span>14.11.&nbsp;Alunbrig (Brigatinib): Takeda Pharmaceuticals<\/span><\/p>\n<p><span>14.11.1.&nbsp;Product Description<\/span><\/p>\n<p><span>14.11.2.&nbsp;Regulatory Milestones<\/span><\/p>\n<p><span>14.11.3.&nbsp;Pivotal Clinical Trials<\/span><\/p>\n<p><span>14.11.4.&nbsp;Ongoing Current Pipeline Activity<\/span><\/p>\n<p><span>14.11.5.&nbsp;Safety and Efficacy of Ongoing Clinical Trials<\/span><\/p>\n<p><span>14.12.&nbsp;Alecensa (Alectinib): Hoffmann-La Roche<\/span><\/p>\n<p><span>14.12.1. Product Description<\/span><\/p>\n<p><span>14.12.2.&nbsp;Regulatory Milestones<\/span><\/p>\n<p><span>14.12.3.&nbsp;Other Developmental Activities<\/span><\/p>\n<p><span>14.12.4.&nbsp;Pivotal Clinical Trials<\/span><\/p>\n<p><span>14.12.5.&nbsp;Ongoing Current Pipeline Activity<\/span><\/p>\n<p><span>14.13.&nbsp;Vitrakvi (Larotrectinib): Bayer Healthcare<\/span><\/p>\n<p><span>14.13.1.&nbsp;Product Description<\/span><\/p>\n<p><span>14.13.2.&nbsp;Regulatory Milestones<\/span><\/p>\n<p><span>14.13.3.&nbsp;Other Developmental Activities<\/span><\/p>\n<p><span>14.13.4.&nbsp;Pivotal Clinical Trials<\/span><\/p>\n<p><span>14.13.5.&nbsp;Safety and Efficacy<\/span><\/p>\n<p><span>14.14.&nbsp;Portrazza (Necitumumab): Eli Lilly<\/span><\/p>\n<p><span>14.14.1.&nbsp;Product Description<\/span><\/p>\n<p><span>14.14.2.&nbsp;Regulatory Milestones<\/span><\/p>\n<p><span>14.14.3.&nbsp;Other Developmental Activities<\/span><\/p>\n<p><span>14.14.4.&nbsp;&nbsp;Pivotal Clinical Trials<\/span><\/p>\n<p><span>14.14.5.&nbsp;&nbsp;Ongoing Current Pipeline Activity<\/span><\/p>\n<p><span>15. Emerging Therapies<\/span><\/p>\n<p><span>15.1. Nazartinib (EGF816): Novartis Pharmaceuticals<\/span><\/p>\n<p><span>15.1.1.&nbsp;Product Description<\/span><\/p>\n<p><span>15.1.2.&nbsp;Clinical Development<\/span><\/p>\n<p><span>15.1.3.&nbsp;Safety and Efficacy<\/span><\/p>\n<p><span>15.2.&nbsp;Capmatinib (INC280): Novartis Pharmaceuticals<\/span><\/p>\n<p><span>15.2.1.&nbsp;Product Description<\/span><\/p>\n<p><span>15.2.2.&nbsp;Other Development Activities<\/span><\/p>\n<p><span>15.2.3.&nbsp;Clinical Development<\/span><\/p>\n<p><span>15.2.4.&nbsp;Safety and Efficacy<\/span><\/p>\n<p><span>15.3.&nbsp;Tepmetko (tepotinib): Merck KGaA<\/span><\/p>\n<p><span>15.3.1.&nbsp;Product Description<\/span><\/p>\n<p><span>15.3.2.&nbsp;Other Development Activities<\/span><\/p>\n<p><span>15.3.3.&nbsp;Clinical Development<\/span><\/p>\n<p><span>15.3.4.&nbsp;Safety and Efficacy<\/span><\/p>\n<p><span>15.4. Merestinib: Eli Lilly and Company<\/span><\/p>\n<p><span>15.4.1.&nbsp;Product Description<\/span><\/p>\n<p><span>15.4.2.&nbsp;Clinical Development<\/span><\/p>\n<p><span>15.4.3.&nbsp;Telisotuzumab Vedotin: AbbVie<\/span><\/p>\n<p><span>15.4.4.&nbsp;Product Description<\/span><\/p>\n<p><span>15.4.5.&nbsp;Clinical Development<\/span><\/p>\n<p><span>15.4.6.&nbsp;Safety and Efficacy<\/span><\/p>\n<p><span>15.5.&nbsp;JNJ-61186372 (JNJ-6372): Janssen Research &amp; Development<\/span><\/p>\n<p><span>15.5.1.&nbsp;Product Description<\/span><\/p>\n<p><span>15.5.2.&nbsp;Other Development Activity<\/span><\/p>\n<p><span>15.5.3.&nbsp;Clinical Development<\/span><\/p>\n<p><span>15.5.4.&nbsp;Safety and Efficacy<\/span><\/p>\n<p><span>15.6.&nbsp;Lazertinib: Yuhan Corporation\/ Janssen Research &amp; Development<\/span><\/p>\n<p><span>15.6.1.&nbsp;Product Description<\/span><\/p>\n<p><span>15.6.2.&nbsp;Clinical Development<\/span><\/p>\n<p><span>15.6.3.&nbsp;Safety and Efficacy<\/span><\/p>\n<p><span>15.7.&nbsp;Vemurafenib Plus Cobimetinib: Hoffmann-La Roche<\/span><\/p>\n<p><span>15.7.1.&nbsp;Product Description<\/span><\/p>\n<p><span>15.7.2.&nbsp;Clinical Development<\/span><\/p>\n<p><span>15.7.3.&nbsp;Safety and Efficacy<\/span><\/p>\n<p><span>15.8.&nbsp;X-396 (Ensartinib): Xcovery<\/span><\/p>\n<p><span>15.8.1.&nbsp;Product Description<\/span><\/p>\n<p><span>15.8.2.&nbsp;Clinical Development<\/span><\/p>\n<p><span>15.8.3.&nbsp;Safety and Efficacy<\/span><\/p>\n<p><span>15.9.&nbsp;Plinabulin: BeyondSpring Pharmaceuticals<\/span><\/p>\n<p><span>15.9.1.&nbsp;Product Description<\/span><\/p>\n<p><span>15.9.2.&nbsp;Clinical Development<\/span><\/p>\n<p><span>15.9.3.&nbsp;Safety and Efficacy<\/span><\/p>\n<p><span>15.10. (OSE2101): OSE Immunotherapeutics<\/span><\/p>\n<p><span>15.10.1. Description<\/span><\/p>\n<p><span>15.10.2.&nbsp;Development<\/span><\/p>\n<p><span>15.10.3&nbsp;&nbsp;Safety and Efficacy<\/span><\/p>\n<p><span>15.11.&nbsp;Selpercatinib (LY3527723\/ LOXO-292): Eli Lilly and Company<\/span><\/p>\n<p><span>15.11.1. Product Description<\/span><\/p>\n<p><span>15.11.2.&nbsp;Clinical Development<\/span><\/p>\n<p><span>15.11.3.&nbsp;Safety and Efficacy<\/span><\/p>\n<p><span>15.12.&nbsp;SAR408701: Sanofi<\/span><\/p>\n<p><span>15.12.1. Product Description<\/span><\/p>\n<p><span>15.12.2.&nbsp;Clinical Development<\/span><\/p>\n<p><span>15.13. Braftovi (encorafinib) + Mektovi (binimetinib): Pfizer<\/span><\/p>\n<p><span>15.13.1. Product Description<\/span><\/p>\n<p><span>15.13.2.&nbsp;Clinical Development<\/span><\/p>\n<p><span>15.14.&nbsp;PADCEV (enfortumab vedotin\/ASG-22ME): Astellas Pharma\/Seattle Genetics<\/span><\/p>\n<p><span>15.14.1.&nbsp;Product Description<\/span><\/p>\n<p><span>15.14.2.&nbsp;Clinical Development<\/span><\/p>\n<p><span>15.15.&nbsp;Pralsetinib (BLU-667): Blueprint Medicines Corporation<\/span><\/p>\n<p><span>15.15.1. Product Description<\/span><\/p>\n<p><span>15.15.2.&nbsp;Clinical Development<\/span><\/p>\n<p><span>15.15.3.&nbsp;Safety and Efficacy<\/span><\/p>\n<p><span>15.16.TAK-788: Takeda<\/span><\/p>\n<p><span>15.16.1.&nbsp;Product Description<\/span><\/p>\n<p><span>15.16.2.&nbsp;Clinical Development<\/span><\/p>\n<p><span>15.16.3.&nbsp;Safety and Efficacy<\/span><\/p>\n<p><span>15.17. Canakinumab (ACZ885): Novartis Pharmaceuticals<\/span><\/p>\n<p><span>15.17.1.&nbsp;Product Description<\/span><\/p>\n<p><span>15.17.2.&nbsp;Clinical Development<\/span><\/p>\n<p><span>15.18.&nbsp;Avelumab (Bavencio): Merck KGaA and Pfizer<\/span><\/p>\n<p><span>15.18.1.&nbsp;Product Description<\/span><\/p>\n<p><span>15.18.2.&nbsp;Clinical Development<\/span><\/p>\n<p><span>15.18.3.&nbsp;Safety and Efficacy<\/span><\/p>\n<p><span>15.19.&nbsp;Veliparib (ABT-888): AbbVie<\/span><\/p>\n<p><span>15.19.1.Product Description<\/span><\/p>\n<p><span>15.19.2.Clinical Development<\/span><\/p>\n<p><span>15.19.3.&nbsp;Safety and Efficacy<\/span><\/p>\n<p><span>15.20.&nbsp;Sitravatinib (MGCD516): Mirati Therapeutics\/Bristol-Myers Squibb\/Beigene<\/span><\/p>\n<p><span>15.20.1. Product Description<\/span><\/p>\n<p><span>15.20.2.&nbsp;Other Developmental Activities<\/span><\/p>\n<p><span>15.20.3. Clinical Development<\/span><\/p>\n<p><span>15.20.4.&nbsp;Safety and Efficacy<\/span><\/p>\n<p><span>15.21.&nbsp;Tesevatinib: Kadmon Corporation<\/span><\/p>\n<p><span>15.21.1.&nbsp;Product Description<\/span><\/p>\n<p><span>15.21.2.&nbsp;Clinical Development<\/span><\/p>\n<p><span>15.21.3.&nbsp;Safety and Efficacy<\/span><\/p>\n<p><span>15.22.&nbsp;Romiplostim: Amgen<\/span><\/p>\n<p><span>15.22.1.&nbsp;Product Description<\/span><\/p>\n<p><span>15.22.2.&nbsp;Clinical Development<\/span><\/p>\n<p><span>15.23.&nbsp;Cabozantinib: Exelixis\/Ipsen\/Takeda<\/span><\/p>\n<p><span>15.23.1.&nbsp;Product Description<\/span><\/p>\n<p><span>15.23.2.&nbsp;Other Development Activities<\/span><\/p>\n<p><span>15.23.3.&nbsp;Clinical Development<\/span><\/p>\n<p><span>15.23.4.&nbsp;Safety and Efficacy<\/span><\/p>\n<p><span>15.24.&nbsp;Sym015: Symphogen<\/span><\/p>\n<p><span>15.24.1.&nbsp;Product Description<\/span><\/p>\n<p><span>15.24.2.&nbsp;Clinical Development<\/span><\/p>\n<p><span>15.24.3.&nbsp;Safety and Efficacy<\/span><\/p>\n<p><span>15.25. AMG 510: Amgen<\/span><\/p>\n<p><span>15.25.1. Product Description<\/span><\/p>\n<p><span>15.25.2.&nbsp;Clinical Development<\/span><\/p>\n<p><span>15.25.3.&nbsp;Safety and Efficacy<\/span><\/p>\n<p><span>15.26. INCMGA00012 (MGA012): Incyte Corporation\/ Zai Lab Limited<\/span><\/p>\n<p><span>15.26.1.&nbsp;Product Description<\/span><\/p>\n<p><span>15.26.2.&nbsp;Clinical Development<\/span><\/p>\n<p><span>15.27.&nbsp;Libtayo (Cemiplimab): Regeneron Pharmaceuticals<\/span><\/p>\n<p><span>15.27.1.&nbsp;Product Description<\/span><\/p>\n<p><span>15.27.2.&nbsp;Clinical Development<\/span><\/p>\n<p><span>15.27.3.&nbsp;Safety and Efficacy<\/span><\/p>\n<p><span>15.28. Bavituximab: Peregrine Pharmaceuticals\/ Avid Bioservices, Inc<\/span><\/p>\n<p><span>15.28.1.&nbsp;Product Description<\/span><\/p>\n<p><span>15.28.2. Clinical Development<\/span><\/p>\n<p><span>15.28.3.&nbsp;Safety and Efficacy<\/span><\/p>\n<p><span>15.29.&nbsp;M7824 (Bintrafusp alfa): GlaxoSmithKline\/Merck KGaA<\/span><\/p>\n<p><span>15.29.1.&nbsp;Product Description<\/span><\/p>\n<p><span>15.29.2.&nbsp;Clinical Development<\/span><\/p>\n<p><span>15.29.3.&nbsp;Safety and Efficacy<\/span><\/p>\n<p><span>16. Non-Small Cell Lung Cancer (NSCLC): Seven Major Market Analysis<\/span><\/p>\n<p><span>16.1.&nbsp;Key Findings<\/span><\/p>\n<p><span>16.2.&nbsp;Market Outlook: 7MM<\/span><\/p>\n<p><span>17. PD-L1&mdash;Market Size<\/span><\/p>\n<p><span>17.1.&nbsp;Total Market Size of PD-L1 NSCLC in the 7MM<\/span><\/p>\n<p><span>17.2.&nbsp;Market Size of PD-L1 NSCLC by Therapeutic Class in the 7MM<\/span><\/p>\n<p><span>17.3.&nbsp;United States Market Size<\/span><\/p>\n<p><span>17.3.1.&nbsp;Total Market size of PD-L1 NSCLC in the United States<\/span><\/p>\n<p><span>17.4.&nbsp;EU-5 Market Size<\/span><\/p>\n<p><span>17.4.1.&nbsp;Germany Market Size<\/span><\/p>\n<p><span>17.4.2.&nbsp;France Market Size<\/span><\/p>\n<p><span>17.4.3.&nbsp;Italy Market Size<\/span><\/p>\n<p><span>17.4.4.&nbsp;Spain Market Size<\/span><\/p>\n<p><span>17.4.5.&nbsp;United Kingdom Market Size<\/span><\/p>\n<p><span>17.5.&nbsp;Japan Market Size<\/span><\/p>\n<p><span>17.5.1.&nbsp;Total Market size of PD-L1 NSCLC in Japan<\/span><\/p>\n<p><span>18. BRAF Mutation&mdash;Market Size<\/span><\/p>\n<p><span>18.1.&nbsp;Total Market Size of BRAF NSCLC in the 7MM<\/span><\/p>\n<p><span>18.2.&nbsp;Market Size of BRAF-NSCLC by Therapeutic Class in the 7MM<\/span><\/p>\n<p><span>18.3.&nbsp;United States Market Size<\/span><\/p>\n<p><span>18.3.1.&nbsp;Total Market size of BRAF NSCLC in the United States<\/span><\/p>\n<p><span>18.4.&nbsp;EU-5 Market Size<\/span><\/p>\n<p><span>18.4.1.&nbsp;Germany Market Size<\/span><\/p>\n<p><span>18.4.2.&nbsp;France Market Size<\/span><\/p>\n<p><span>18.4.3.&nbsp;Italy Market Size<\/span><\/p>\n<p><span>18.4.4.&nbsp;Spain Market Size<\/span><\/p>\n<p><span>18.4.5.&nbsp;United Kingdom Market Size<\/span><\/p>\n<p><span>18.5.&nbsp;Japan Market Size<\/span><\/p>\n<p><span>18.5.1.&nbsp;Total Market size of BRAF NSCLC in Japan<\/span><\/p>\n<p><span>19. c-MET Mutation&mdash;Market Size<\/span><\/p>\n<p><span>19.1.&nbsp;Total Market Size of c-MET NSCLC in the 7MM<\/span><\/p>\n<p><span>19.2.&nbsp;Market Size of c-MET NSCLC by Therapeutic Class in the 7MM<\/span><\/p>\n<p><span>19.3.&nbsp;United States Market Size<\/span><\/p>\n<p><span>19.3.1.&nbsp;Total Market size of c-MET NSCLC in the United States<\/span><\/p>\n<p><span>19.4.&nbsp;EU-5 Market Size<\/span><\/p>\n<p><span>19.4.1.&nbsp;Germany Market Size<\/span><\/p>\n<p><span>19.4.2.&nbsp;France Market Size<\/span><\/p>\n<p><span>19.4.3.&nbsp;Italy Market Size<\/span><\/p>\n<p><span>19.4.4.&nbsp;Spain Market Size<\/span><\/p>\n<p><span>19.4.5.&nbsp;United Kingdom Market Size<\/span><\/p>\n<p><span>19.5. Japan Market Size<\/span><\/p>\n<p><span>19.5.1.&nbsp;Total Market size of c-MET NSCLC in Japan<\/span><\/p>\n<p><span>20. EGFR Mutation&mdash;Market Size<\/span><\/p>\n<p><span>20.1.&nbsp;Total Market Size of EGFR-positive NSCLC in the 7MM<\/span><\/p>\n<p><span>20.2.&nbsp;Market Size of EGFR-positive NSCLC by Therapeutic Class in the 7MM<\/span><\/p>\n<p><span>20.3.&nbsp;United States Market Size<\/span><\/p>\n<p><span>20.3.1.&nbsp;Total Market size of EGFR NSCLC in the United States<\/span><\/p>\n<p><span>20.4.&nbsp;EU-5 Market Size<\/span><\/p>\n<p><span>20.4.1.&nbsp;Germany Market Size<\/span><\/p>\n<p><span>20.4.2.&nbsp;France Market Size<\/span><\/p>\n<p><span>20.4.3.&nbsp;Italy Market Size<\/span><\/p>\n<p><span>20.4.4.&nbsp;Spain Market Size<\/span><\/p>\n<p><span>20.4.5.&nbsp;United Kingdom Market Size<\/span><\/p>\n<p><span>20.5.&nbsp;Japan Market Size<\/span><\/p>\n<p><span>20.5.1.&nbsp;Total Market size of NSCLC in Japan<\/span><\/p>\n<p><span>21. ALK-Mutation&mdash;Market Size<\/span><\/p>\n<p><span>21.1.&nbsp;Total Market Size of ALK NSCLC in the 7MM<\/span><\/p>\n<p><span>21.2.&nbsp;Market Size of ALK NSCLC by Therapeutic Class in the 7MM<\/span><\/p>\n<p><span>21.3.&nbsp;United States Market Size<\/span><\/p>\n<p><span>21.3.1.&nbsp;Total Market size of ALK NSCLC in the United States<\/span><\/p>\n<p><span>21.4.&nbsp;EU-5 Market Size<\/span><\/p>\n<p><span>21.4.1.&nbsp;Germany Market Size<\/span><\/p>\n<p><span>21.4.2.&nbsp;France Market Size<\/span><\/p>\n<p><span>21.4.3.&nbsp;Italy Market Size<\/span><\/p>\n<p><span>21.4.4.&nbsp;Spain Market Size<\/span><\/p>\n<p><span>21.4.5.&nbsp;United Kingdom Market Size<\/span><\/p>\n<p><span>21.5.&nbsp;Japan Market Size<\/span><\/p>\n<p><span>21.5.1.&nbsp;Total Market size of NSCLC in Japan<\/span><\/p>\n<p><span>22. Market Access and Reimbursement of NSCLC Therapies<\/span><\/p>\n<p><span>23. Market Drivers of NSCLC<\/span><\/p>\n<p><span>24. Market Barriers of NSCLC<\/span><\/p>\n<p><span>25. Appendix<\/span><\/p>\n<p><span>25.1. Bibliography<\/span><\/p>\n<p><span>25.2.&nbsp;Report Methodology<\/span><\/p>\n<p><span>26. DelveInsight Capabilities<\/span><\/p>\n<p><span>27. Disclaimer<\/span><\/p>\n<p><span>28. About DelveInsight<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"post-details-shared p-15\" style=\"text-align: justify;\"><strong>Related Reports:<\/strong><\/div>\n<ul style=\"text-align: justify;\">\n<li><em><span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-epidemiology-forecast\"  target=\"_blank\">Non-Small Cell Lung Cancer Epidemiology Forecast to 2030<\/a><\/span><\/em><\/li>\n<li><em><span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape\"  target=\"_blank\">Non-Small Cell Lung Cancer Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020<\/a><\/span><\/em><\/li>\n<li><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-pipeline-insight\"  target=\"_blank\">Non-Small Cell Lung Cancer Pipeline Insights, 2020<\/a><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong>&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=nonsmall-cell-lung-cancer-market-is-expected-to-increase-with-a-cagr-of-107-for-the-study-period-of-20172030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=nonsmall-cell-lung-cancer-market-is-expected-to-increase-with-a-cagr-of-107-for-the-study-period-of-20172030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u2018Non-Small Cell Lung Cancer (NSCLC) &#8211; Market Insights, Epidemiology and Market Forecast &#8211; 2030\u2019 report delivers an in-depth understanding of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Non-Small Cell &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/nonsmall-cell-lung-cancer-market-is-expected-to-increase-with-a-cagr-of-107-for-the-study-period-of-20172030_495862.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-495862","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/495862","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=495862"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/495862\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=495862"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=495862"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=495862"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}